Louisiana State Employees Retirement System Buys New Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)

Louisiana State Employees Retirement System acquired a new stake in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 64,500 shares of the biopharmaceutical company's stock, valued at approximately $1,509,000.

Several other institutional investors also recently modified their holdings of the stock. NBC Securities Inc. lifted its stake in shares of TG Therapeutics by 58.9% in the third quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company's stock worth $30,000 after buying an additional 485 shares in the last quarter. Blue Trust Inc. grew its stake in TG Therapeutics by 127.3% in the 3rd quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company's stock valued at $35,000 after acquiring an additional 849 shares during the period. Ashton Thomas Private Wealth LLC acquired a new position in TG Therapeutics in the second quarter valued at approximately $35,000. ORG Wealth Partners LLC purchased a new stake in shares of TG Therapeutics during the third quarter worth approximately $53,000. Finally, Values First Advisors Inc. purchased a new position in shares of TG Therapeutics during the third quarter worth about $58,000. 58.58% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms have issued reports on TGTX. TD Cowen initiated coverage on TG Therapeutics in a report on Tuesday. They set a "buy" rating and a $50.00 price objective on the stock. The Goldman Sachs Group lifted their price target on shares of TG Therapeutics from $18.00 to $20.00 and gave the company a "neutral" rating in a research note on Wednesday, August 7th. B. Riley raised their price target on shares of TG Therapeutics from $29.00 to $34.00 and gave the company a "buy" rating in a research note on Wednesday, August 7th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $49.00 price target on shares of TG Therapeutics in a research report on Wednesday, September 18th. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $34.43.

TG Therapeutics Price Performance

NASDAQ:TGTX traded up $1.84 during mid-day trading on Friday, hitting $26.90. The company's stock had a trading volume of 5,713,973 shares, compared to its average volume of 3,619,056. The company has a current ratio of 3.58, a quick ratio of 2.83 and a debt-to-equity ratio of 0.58. TG Therapeutics, Inc. has a fifty-two week low of $9.81 and a fifty-two week high of $26.99. The stock has a fifty day moving average of $23.44 and a 200-day moving average of $19.89. The company has a market capitalization of $4.16 billion, a price-to-earnings ratio of 43.56 and a beta of 2.21.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last posted its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.04 earnings per share for the quarter, topping analysts' consensus estimates of ($0.04) by $0.08. The business had revenue of $73.47 million for the quarter, compared to the consensus estimate of $65.92 million. TG Therapeutics had a return on equity of 57.73% and a net margin of 27.60%. The firm's revenue for the quarter was up 357.0% on a year-over-year basis. During the same period in the prior year, the business earned ($0.34) EPS. As a group, equities analysts forecast that TG Therapeutics, Inc. will post 0.12 EPS for the current fiscal year.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.